TRPV4 deficiency causes sexual dimorphism in bone metabolism and osteoporotic fracture risk

Bone

Volumn 57, Issue 2, 2013, Pages 443-454

  Van der Eerden, B C J ^a   Oei, L ^a   Roschger, P ^b   Fratzl Zelman, N ^b   Hoenderop, J G J ^c   van Schoor, N M ^d   Pettersson Kymmer, U ^e   Schreuders Koedam, M ^a   Uitterlinden, A G ^a   Hofman, A ^a   Suzuki, M ^f   Klaushofer, K ^b   Ohlsson, C ^g   Lips, P J A ^d   Rivadeneira, F ^a   Bindels, R J M ^c   van Leeuwen, J P T M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HANUSCH HOSPITAL   (Austria)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UMEÅ UNIVERSITY   (Sweden)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bone; Fracture risk; Osteoporosis; Sexual dimorphism; TRPV4

Indexed keywords

PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; VANILLOID RECEPTOR 4;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE STRENGTH; BONE STRESS; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FEMUR; FRAGILITY FRACTURE; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCYTE; OSTEOID; POROSITY; PROTEIN BLOOD LEVEL; RIGIDITY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRABECULAR BONE; TRPV4 GENE; WILD TYPE;

BONE; FRACTURE RISK; OSTEOPOROSIS; SEXUAL DIMORPHISM; TRPV4;

ANIMALS; BONE AND BONES; ELASTIC MODULUS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; NETHERLANDS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROTIC FRACTURES; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEX CHARACTERISTICS; STRESS, MECHANICAL; TRPV CATION CHANNELS;

EID: 84885794712     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.09.017     Document Type: Article

References (67)

1. Hoenderop J.G., van Leeuwen J.P., van der Eerden B.C., Kersten F.F., van der Kemp A.W., Merillat A.M., et al. Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 2003, 112:1906-1914.
2. van der Eerden B.C., Hoenderop J.G., de Vries T.J., Schoenmaker T., Buurman C.J., Uitterlinden A.G., et al. The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption. Proc Natl Acad Sci U S A 2005, 102:17507-17512.
3. Bianco S.D., Peng J.B., Takanaga H., Suzuki Y., Crescenzi A., Kos C.H., et al. Marked disturbance of calcium homeostasis in mice with targeted disruption of the trpv6 calcium channel gene. J Bone Miner Res 2007, 22:274-285.
4. van der Eerden B.C., Weissgerber P., Fratzl-Zelman N., Olausson J., Hoenderop J.G., Schreuders-Koedam M., et al. The transient receptor potential channel TRPV6 is dynamically expressed in bone cells but is not crucial for bone mineralization in mice. J Cell Physiol 2012, 227:1951-1959.
5. Lieben L., Benn B.S., Ajibade D., Stockmans I., Moermans K., Hediger M.A., et al. Trpv6 mediates intestinal calcium absorption during calcium restriction and contributes to bone homeostasis. Bone 2010, 47:301-308.
6. Strotmann R., Harteneck C., Nunnenmacher K., Schultz G., Plant T.D. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol 2000, 2:695-702.
7. Nilius B. TRP channels in disease. Biochim Biophys Acta 2007, 1772:805-812.
8. Liedtke W. Transient receptor potential vanilloid channels functioning in transduction of osmotic stimuli. J Endocrinol 2006, 191:515-523.
9. Rock M.J., Prenen J., Funari V.A., Funari T.L., Merriman B., Nelson S.F., et al. Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. Nat Genet 2008, 40:999-1003.
10. Bellido T., Huening M., Raval-Pandya M., Manolagas S.C., Christakos S. Calbindin-D28k is expressed in osteoblastic cells and suppresses their apoptosis by inhibiting caspase-3 activity. J Biol Chem 2000, 275:26328-26332.
11. Masuyama R., Vriens J., Voets T., Karashima Y., Owsianik G., Vennekens R., et al. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclasts. Cell Metab 2008, 8:257-265.
12. Mizoguchi F., Mizuno A., Hayata T., Nakashima K., Heller S., Ushida T., et al. Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone loss. J Cell Physiol 2008, 216:47-53.
13. Callewaert F., Venken K., Kopchick J.J., Torcasio A., van Lenthe G.H., Boonen S., et al. Sexual dimorphism in cortical bone size and strength but not density is determined by independent and time-specific actions of sex steroids and IGF-1: evidence from pubertal mouse models. J Bone Miner Res 2010, 25:617-626.
14. Suzuki M., Mizuno A., Kodaira K., Imai M. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem 2003, 278:22664-22668.
15. Bouxsein M.L., Boyd S.K., Christiansen B.A., Guldberg R.E., Jepsen K.J., Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010, 25:1468-1486.
16. Westbroek I., Waarsing J.H., van Leeuwen J.P., Waldum H., Reseland J.E., Weinans H., et al. Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 2007, 101:360-368.
17. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595-608.
18. Roschger P., Paschalis E.P., Fratzl P., Klaushofer K. Bone mineralization density distribution in health and disease. Bone 2008, 42:456-466.
19. Roschger P., Fratzl P., Eschberger J., Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 1998, 23:319-326.
20. Gruber H.E. Adaptations of Goldner's Masson trichrome stain for the study of undecalcified plastic embedded bone. Biotech Histochem 1992, 67:30-34.
21. Eijken M., Hewison M., Cooper M.S., de Jong F.H., Chiba H., Stewart P.M., et al. 11beta-hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation. Mol Endocrinol 2005, 19:621-631.
22. de Vries T.J., Schoenmaker T., Beertsen W., van der Neut R., Everts V. Effect of CD44 deficiency on in vitro and in vivo osteoclast formation. J Cell Biochem 2005, 94:954-966.
23. Hofman A., Grobbee D.E., de Jong P.T., van den Ouweland F.A. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991, 7:403-422.
24. Hofman A., van Duijn C.M., Franco O.H., Ikram M.A., Janssen H.L., Klaver C.C., et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 2011, 26:657-686.
25. Weel A.E., Uitterlinden A.G., Westendorp I.C., Burger H., Schuit S.C., Hofman A., et al. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999, 84:3146-3150.
26. Rivadeneira F., van Meurs J.B., Kant J., Zillikens M.C., Stolk L., Beck T.J., et al. Estrogen receptor beta (ESR2) polymorphisms in interaction with estrogen receptor alpha (ESR1) and insulin-like growth factor I (IGF1) variants influence the risk of fracture in postmenopausal women. J Bone Miner Res 2006, 21:1443-1456.
27. Rivadeneira F., Styrkarsdottir U., Estrada K., Halldorsson B.V., Hsu Y.H., Richards J.B., et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009, 41:1199-1206.
28. Devlin B., Roeder K. Genomic control for association studies. Biometrics 1999, 55:997-1004.
29. Huisman M., Poppelaars J., van der Horst M., Beekman A.T., Brug J., van Tilburg T.G., et al. Cohort profile: the longitudinal aging study Amsterdam. Int J Epidemiol 2011, 40:868-876.
30. Mellstrom D., Johnell O., Ljunggren O., Eriksson A.L., Lorentzon M., Mallmin H., et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006, 21:529-535.
31. Mellstrom D., Vandenput L., Mallmin H., Holmberg A.H., Lorentzon M., Oden A., et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008, 23:1552-1560.
32. Hallmans G., Agren A., Johansson G., Johansson A., Stegmayr B., Jansson J.H., et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. Scand J Public Health Suppl 2003, 61:18-24.
33. Englund U., Nordstrom P., Nilsson J., Bucht G., Bjornstig U., Hallmans G., et al. Physical activity in middle-aged women and hip fracture risk: the UFO study. Osteoporos Int 2011, 22:499-505.
34. Rivadeneira F., Houwing-Duistermaat J.J., Beck T.J., Janssen J.A., Hofman A., Pols H.A., et al. The influence of an insulin-like growth factor I gene promoter polymorphism on hip bone geometry and the risk of nonvertebral fracture in the elderly: the Rotterdam Study. J Bone Miner Res 2004, 19:1280-1290.
35. Masuyama R., Mizuno A., Komori H., Kajiya H., Uekawa A., Kitaura H., et al. Calcium/calmodulin-signaling supports TRPV4 activation in osteoclasts and regulates bone mass. J Bone Miner Res 2012, 27:1708-1721.
36. O'Conor C.J., Griffin T.M., Liedtke W., Guilak F. Increased susceptibility of Trpv4-deficient mice to obesity and obesity-induced osteoarthritis with very high-fat diet. Ann Rheum Dis 2013, 72:300-304.
37. Nicolaije C., Koedam M., van Leeuwen J.P. Decreased oxygen tension lowers reactive oxygen species and apoptosis and inhibits osteoblast matrix mineralization through changes in early osteoblast differentiation. J Cell Physiol 2012, 227:1309-1318.
38. Zebaze R.M., Ghasem-Zadeh A., Bohte A., Iuliano-Burns S., Mirams M., Price R.I., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
39. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001, 12:989-995.
40. Ohishi M., Chiusaroli R., Ominsky M., Asuncion F., Thomas C., Khatri R., et al. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Am J Pathol 2009, 174:2160-2171.
41. Morko J., Kiviranta R., Hurme S., Rantakokko J., Vuorio E. Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K. Bone 2005, 36:854-865.
42. Schinke T., Schilling A.F., Baranowsky A., Seitz S., Marshall R.P., Linn T., et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med 2009, 15:674-681.
43. Teti A., Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone 2009, 44:11-16.
44. Bonewald L.F. The amazing osteocyte. J Bone Miner Res 2011, 26:229-238.
45. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone Miner Metab 2008, 26:1-8.
46. Fratzl P., Gupta H.S., Paschalis E., Roschger P. Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem 2004, 14:2115-2123.
47. Fratzl P., Roschger P., Fratzl-Zelman N., Paschalis E.P., Phipps R., Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int 2007, 81:73-80.
48. Karasik D., Ferrari S.L. Contribution of gender-specific genetic factors to osteoporosis risk. Ann Hum Genet 2008, 72:696-714.
49. Deng H.W., Mahaney M.C., Williams J.T., Li J., Conway T., Davies K.M., et al. Relevance of the genes for bone mass variation to susceptibility to osteoporotic fractures and its implications to gene search for complex human diseases. Genet Epidemiol 2002, 22:12-25.
50. Kanis J.A., Oden A., Johnell O., De Laet C., Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004, 15:108-112.
51. van Meurs J.B., Schuit S.C., Weel A.E., van der K.M., Bergink A.P., Arp P.P., et al. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet 2003, 12:1745-1754.
52. Hoorn E.J., Rivadeneira F., van Meurs J.B., Ziere G., Stricker B.H., Hofman A., et al. Mild hyponatremia as a risk factor for fractures: the Rotterdam Study. J Bone Miner Res 2011, 26:1822-1828.
53. Verbalis J.G., Barsony J., Sugimura Y., Tian Y., Adams D.J., Carter E.A., et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010, 25:554-563.
54. Barsony J., Sugimura Y., Verbalis J.G. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss. J Biol Chem 2011, 286:10864-10875.
55. Kirmani S., Christen D., van Lenthe G.H., Fischer P.R., Bouxsein M.L., McCready L.K., et al. Bone structure at the distal radius during adolescent growth. J Bone Miner Res 2009, 24:1033-1042.
56. Nishiyama K.K., Macdonald H.M., Moore S.A., Fung T., Boyd S.K., McKay H.A. Cortical porosity is higher in boys compared with girls at the distal radius and distal tibia during pubertal growth: an HR-pQCT study. J Bone Miner Res 2012, 27:273-282.
57. Seeman E. Structural basis of growth-related gain and age-related loss of bone strength. Rheumatology (Oxford) 2008, 47(Suppl. 4):iv2-iv8.
58. Parfitt A.M. The two faces of growth: benefits and risks to bone integrity. Osteoporos Int 1994, 4:382-398.
59. Fratzl-Zelman N., Roschger P., Misof B.M., Nawrot-Wawrzyniak K., Potter-Lang S., Muschitz C., et al. Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover. Calcif Tissue Int 2011, 88:378-387.
60. Misof B.M., Patsch J.M., Roschger P., Muschitz C., Gamsjaeger S., Paschalis E.P., et al. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. J Bone Miner Res 2013, 10.1002/jbmr.2035.
61. Diderich K.E., Nicolaije C., Priemel M., Waarsing J.H., Day J.S., Brandt R.M., et al. Bone fragility and decline in stem cells in prematurely aging DNA repair deficient trichothiodystrophy mice. Age (Dordr) 2012, 34:845-861.
62. Nishimura G., Lausch E., Savarirayan R., Shiba M., Spranger J., Zabel B., et al. TRPV4-associated skeletal dysplasias. Am J Med Genet C Semin Med Genet 2012, 160C:190-204.
63. Scheller E.L., Song J., Dishowitz M.I., Hankenson K.D., Krebsbach P.H. A potential role for the myeloid lineage in leptin-regulated bone metabolism. Horm Metab Res 2012, 44:1-5.
64. Xu Z.P., Gao W.C., Wang H.P., Wang X.H. Expression of transient receptor potential subfamily mRNAs in rat testes. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:519-520.
65. Lee H., Caterina M.J. TRPV channels as thermosensory receptors in epithelial cells. Pflugers Arch 2005, 451:160-167.
66. -/- mice. Mol Pain 2007, 3:31.
67. Wijchers P.J., Festenstein R.J. Epigenetic regulation of autosomal gene expression by sex chromosomes. Trends Genet 2011, 27:132-140.